
Myasthenia Gravis- Pipeline Insight, 2025
Description
DelveInsight’s, “Myasthenia Gravis- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Myasthenia Gravis: Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body's immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.
Signs and symptoms of myasthenia gravis can vary widely but often include drooping of one or both eyelids (ptosis), double vision (diplopia), difficulty speaking, chewing, or swallowing, weakness in the arms or legs, and fatigue that worsens with activity but improves with rest. Symptoms may worsen over the course of the day or after physical exertion.
The exact cause of myasthenia gravis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immunological factors. Certain risk factors may increase the likelihood of developing MG, including being female (it's more common in women), having a family history of the condition, and having other autoimmune disorders like thyroid disease or lupus.
Diagnosing myasthenia gravis typically involves a thorough medical history, physical examination, and specialized tests such as electromyography (EMG), nerve conduction studies, blood tests to check for specific antibodies, and the edrophonium test, which involves injecting a medication to temporarily improve muscle strength. Treatment for myasthenia gravis aims to manage symptoms, improve muscle strength, and prevent complications. This may include medications to suppress the immune system's abnormal response (such as corticosteroids or immunosuppressants), medications that improve nerve-to-muscle communication (such as pyridostigmine), plasmapheresis to remove antibodies from the blood, intravenous immunoglobulin (IVIG) therapy, or, in some cases, surgery to remove the thymus gland (thymectomy). With proper treatment, many people with myasthenia gravis can lead relatively normal lives. However, ongoing management and monitoring are usually necessary to adjust treatment as needed and manage potential complications.
""Myasthenia Gravis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myasthenia Gravis Emerging Drugs
Further product details are provided in the report……..
Myasthenia Gravis: Therapeutic Assessment
This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:
Myasthenia Gravis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.
Myasthenia Gravis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Myasthenia Gravis: Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body's immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.
Signs and symptoms of myasthenia gravis can vary widely but often include drooping of one or both eyelids (ptosis), double vision (diplopia), difficulty speaking, chewing, or swallowing, weakness in the arms or legs, and fatigue that worsens with activity but improves with rest. Symptoms may worsen over the course of the day or after physical exertion.
The exact cause of myasthenia gravis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immunological factors. Certain risk factors may increase the likelihood of developing MG, including being female (it's more common in women), having a family history of the condition, and having other autoimmune disorders like thyroid disease or lupus.
Diagnosing myasthenia gravis typically involves a thorough medical history, physical examination, and specialized tests such as electromyography (EMG), nerve conduction studies, blood tests to check for specific antibodies, and the edrophonium test, which involves injecting a medication to temporarily improve muscle strength. Treatment for myasthenia gravis aims to manage symptoms, improve muscle strength, and prevent complications. This may include medications to suppress the immune system's abnormal response (such as corticosteroids or immunosuppressants), medications that improve nerve-to-muscle communication (such as pyridostigmine), plasmapheresis to remove antibodies from the blood, intravenous immunoglobulin (IVIG) therapy, or, in some cases, surgery to remove the thymus gland (thymectomy). With proper treatment, many people with myasthenia gravis can lead relatively normal lives. However, ongoing management and monitoring are usually necessary to adjust treatment as needed and manage potential complications.
""Myasthenia Gravis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve Myasthenia Gravis.
This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myasthenia Gravis Emerging Drugs
- HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
- KYV-101: Kyverna Therapeutics
- CABA-201: Cabaletta Bio
Further product details are provided in the report……..
Myasthenia Gravis: Therapeutic Assessment
This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myasthenia Gravis
- There are approx. 20+ key companies which are developing the therapies for Myasthenia Gravis. The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Preregistration include, Harbour BioMed (Guangzhou) Co. Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Myasthenia Gravis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.
Myasthenia Gravis Report Insights
- Myasthenia Gravis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myasthenia Gravis drugs?
- How many Myasthenia Gravis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myasthenia Gravis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myasthenia Gravis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Harbour BioMed (Guangzhou) Co. Ltd.
- Kyverna Therapeutics
- Cabaletta Bio
- Takeda
- Hoffmann-La Roche
- Immunovant Sciences GmbH
- Regeneron Pharmaceuticals
- Novartis Pharmaceuticals
- Janssen Research & Development, LLC
- Momenta Pharmaceuticals, Inc.
- Amgen
- Dianthus Therapeutics
- Cartesian Therapeutics
- COUR Pharmaceutical Development Company, Inc.
- Alexion Pharmaceuticals, Inc
- HBM9161
- KYV-101
- CABA-201
- TAK-079
- Satralizumab
- RVT-1401
- Pozelimab
- CFZ533
- Nipocalimab
- M281
- Inebilizumab
- DNTH103
- Descartes-08
- CNP-106
- ALXN1720
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Myasthenia Gravis: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Myasthenia Gravis– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- KYV-101: Kyverna Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- CABA-201: Cabaletta Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Myasthenia Gravis Key Companies
- Myasthenia Gravis Key Products
- Myasthenia Gravis- Unmet Needs
- Myasthenia Gravis- Market Drivers and Barriers
- Myasthenia Gravis- Future Perspectives and Conclusion
- Myasthenia Gravis Analyst Views
- Myasthenia Gravis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.